NPM1 and chronic myelomonocytic leukemia: The presence of NPM1 mutation (~5% of patients) calls for reconsideration of the diagnosis of CMML, as AML-M4 can masquerade initially as CMML, and intensive chemotherapy could be used in younger, fitter patients or combination treatment with azacitidine plus venetoclax in older individuals (13, 60).